Shots:

• oNKo-innate to receive an up front- clinical- regulatory & commercial milestones along with royalties on sales of immuno-oncology and cell therapy programs while in exchange- the company will utilize its genome-wide screening techniques and technology platform to discover novel immune cell targets enhancing NK cell anti-tumor immunity and to create NK cell therapies
• oNKo-innate will execute screens to identify and validate targets to seed internal Gilead’s immuno-oncology discovery programs. For Kite’s development of next-generation cell therapies- oNKo-innate will create and evaluate NK constructs
• The alliance will expand Kite’s capabilities to identify NK cell therapies and advance it toward clinical development while supports Gilead’s efforts to develop novel cancer therapies

Click here ­to­ read full press release/ article 

Ref: Gilead  | Image: Gilead